Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years. Dasiglucagon will be administered as a subcutaneous infusion. To be eligible, subjects are to have at least 3 or more hypoglycemic events a week, and are to have undergone a pancreatectomy for hyperinsulinism or are being treated with a non-surgical approach, because they were not eligible for pancreatic surgery.